Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Eligibility


Inclusion Criteria:

   - Patients older than 18-year-old, diagnosed with cancer

   - Patients must understand and voluntarily sign an Informed Consent form after the
   contents have been fully explained to them

Exclusion Criteria:

   - Patients who cannot complete a PET/CT scan

   - Pregnant women

   - Healthy volunteers

   - Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to
the subjects.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
650-736-2859
Recruiting